Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. Until today this year the stock’s price performance recorded an increase of 12.33%. However, over the last six months, the performance has been weaker by 10.68%. The price of LIXT decreased -0.87% over the last 30 days. And in the last five days, it has fallen by -16.79%.
Lixte Biotechnology Holdings Inc experienced a somewhat steady performance in the stock market. The company’s stock reached a 1-year high of $4.40 on 03/27/24, while the lowest price for the same period was registered at $1.31 on 10/28/24.
52-week price history of LIXT Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Lixte Biotechnology Holdings Inc’s current trading price is -48.18% away from its 52-week high, while its distance from the 52-week low is 74.05%. The stock’s price range during this period has varied between$1.31 and $4.40. The Lixte Biotechnology Holdings Inc’s shares, which operate in the Healthcare, saw a trading volume of around 10781.0 for the day, a figure considerably lower than their average daily volume of 23560.0 over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Lixte Biotechnology Holdings Inc (LIXT) has experienced a quarterly rise of 25.97% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 5.13M and boasts a workforce of 4 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.03, with a change in price of +0.24. Similarly, Lixte Biotechnology Holdings Inc recorded 377,876 in trading volume during the last 100 days, posting a change of +11.76%.
LIXT’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for LIXT stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
LIXT Stock Stochastic Average
As of today, Lixte Biotechnology Holdings Inc’s raw stochastic average for the last 50 days stands at 40.00%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 3.99%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 35.89% and 50.35%, respectively.